证券代码：300702 证券简称：天宇股份 公告编号：2025-040 浙江天宇药业股份有限公司 关于控股股东、实际控制人之一致行动人减持股份 的预披露公告 信息披露义务人控股股东、实际控制人之一致行动人屠善增保证信息披露 的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 浙江天宇药业股份有限公司（以下简称"公司"）于近日收到控股股东、实 际控制人之一致行动人屠善增先生的《关于公司股份减持计划的告知函》，屠善 增先生持有公司股份 10,479,056 股（占公司总股本的比例为 3.01%），计划在自 本公告披露之日起十五个交易日后的三个月内（即 2025 年 7 月 18 日至 2025 年 10 月 15 日），以集中竞价方式减持公司股份不超过 3,479,771 股（占本公司总 股本比例 1.00%），以大宗交易方式减持公司股份不超过 6,959,543 股（占本公司 总股本比例 2.00%）。现将有关情况公告如下： 二、本次减持计划的主要内容 （一）本次减持计划的具体安排 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 ...

一、药品基本情况 药品名称：厄贝沙坦（工艺 II） 药品生产商/持有人：浙江天宇药业股份有限公司 生产地址：浙江省台州市 证书编号：CEP 2025-025 - Rev 00 发证机构：欧洲药品质量管理局 有效期：自 2025 年 5 月 15 日起五年内 二、药品的其他相关情况 厄贝沙坦属于降血压药物，治疗原发性高血压，合并高血压的 2 型糖尿病肾 病的治疗。 证券代码：300702 证券简称：天宇股份 公告编号：2025-040 浙江天宇药业股份有限公司 关于公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局 （以下简称"EDQM"）签发的关于厄贝沙坦（工艺 II）原料药的欧洲药典适用 性认证证书（以下简称"CEP 证书"），现将相关情况公告如下： 公司于 2024 年 12 月向 EDQM 递交了厄贝沙坦（工艺 II）原料药的药品注 册申请并获得 CEP 证书。 三、对公司的影响及风险提示 截至目前，公司厄贝沙坦原料药共 ...

浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 证券代码：300702 证券简称：天宇股份 公告编号：2025-039 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于孟鲁司特钠片的《药品注册证书》。现将相关 情况公告如下： 一、药品情况 1、药品基本情况 | 药品名称 | 孟鲁司特钠片 | | | | --- | --- | --- | --- | | 英文名 | Montelukast Sodium Tablets | | | | 剂型 | 片剂 | | | | 规格 | 10mg（按 C35H36ClNO3S | | 计） | | 是否处方药 | 是 | | | | 申请事项 | 药品注册（境内生产） | | | | 注册分类 | 化学药品 类 4 | | | | 药品批准文号 | 国药准字 H20254487 | | | | 药品批准文号 ...

Core Viewpoint - Tianyu Co., Ltd. has received the European Pharmacopoeia Certificate of Suitability (CEP) for its raw material drug Eprosartan, which is used for treating primary hypertension and diabetic nephropathy associated with hypertension [1] Group 1 - The company submitted its drug registration application in December 2024 and obtained the CEP certificate, numbered CEP2025-025-Rev00, which is valid for five years starting from May 15, 2025 [1] - Eprosartan is classified as an antihypertensive medication, indicating its significance in the treatment of high blood pressure [1] - The company now holds two CEP certificates for Eprosartan raw materials, which is expected to positively impact its efforts to expand into international markets [1]

1、经公司 2024 年度股东大会审议通过的利润分配预案为：公司本次的利润 分配以实施权益分派股权登记日登记的享有利润分配权的股本为基数，向全体股 东每 10 股派发现金股利 0.5 元（含税）,其余未分配利润结转下年。本次利润分 配不送红股、不进行资本公积金转增股本。自本公告披露至利润分配方案实施前， 若公司前述总股数由于股份回购等情形而发生变化,公司将按照"分配比例不变" 的原则,相应调整分配总额。截至本公告日，公司总股本为 347,977,159 股，合 计派发现金红利总金额为 17,398,857.95 元（含税）。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一致。 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个月。 证券代码：300702 证券简称：天宇股份 公告编号：2025-038 浙江天宇药业股份有限公司 关于 2024 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下 ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-037 浙江天宇药业股份有限公司 关于 2024 年员工持股计划第一个锁定期届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称公司）《2024 年员工持股计划》（以 下简称"本次员工持股计划"或"本计划"）第一个锁定期将于 2025 年 5 月 28 日届满。根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定及 本次员工持股计划的相关内容，现将本次员工持股计划第一个锁定期届满及解锁 情况公告如下： 一、本次员工持股计划的基本情况 （一）本次员工持股计划的基本情况 公司于 2024 年 2 月 21 日召开第五届董事会第六次会议和第五届监事会第 六次会议，审议通过《关于<浙江天宇药业股份有限公司 2024 年员工持股计划 （草案）>及其摘要的议案》《关于<浙江天宇药业股份有限公司 2024 年员工持 股计划管理办法>的议案》等相关 ...

Group 1: Financial Performance - The company's CDMO business revenue for 2025 is projected at 136 million yuan, showing a decline of approximately 4% compared to the previous year, indicating stable market demand [2] - The company has invested 105 million yuan in formulation R&D for 2024, with capitalized expenditures amounting to 23.9 million yuan [3] - The formulation business is expected to reduce losses by approximately 40 million yuan in 2024 compared to 2023 [3] Group 2: Market Position and Growth - The company achieved a sales volume of 1,744 tons for sartans in 2024, capturing about 24% of the global market demand of 7,233 tons [7] - Non-sartan revenue reached 559 million yuan in 2024, reflecting a growth of 45.5% compared to 2023, indicating a strong upward trend [7] - The company has obtained 63 formulation approvals, enhancing its product pipeline and market presence [8] Group 3: Customer Concentration - The combined sales from the top five customers accounted for 40.18% of total sales in 2024, a decrease from 44.97% in 2023, with no significant change exceeding 10 percentage points [6] Group 4: Strategic Initiatives - The company has not introduced third-party platform traffic resources for e-commerce channels [4] - Continuous investment in CDMO R&D is planned for 2024, with projected revenue of 366 million yuan primarily serving original drug companies during patent periods [5]

Industry Overview - The cholesterol-lowering drug industry is crucial for preventing and treating cardiovascular diseases, with a growing patient population due to aging and increasing rates of dyslipidemia [1][8] - The prevalence of dyslipidemia among the elderly is high, with 47% of individuals over 60 affected, while the rate among those aged 18 and above has risen from 18.6% in 2002 to 35.6% in 2023 [8][10] Market Development - The cholesterol-lowering drug market in China is projected to grow from CNY 252.94 billion in 2023 to CNY 265.95 billion in 2024, despite a slowdown due to national procurement policies [10][20] - Sales distribution shows that 57% of sales come from hospitals, while 43% are from retail markets [10] Drug Categories - Cholesterol-lowering drugs are categorized into statins, fibrates, niacin, bile acid sequestrants, PCSK9 inhibitors, and monoclonal antibodies targeting angiopoietin-like protein 3 [3][12] - Statins dominate the market with a 76.58% share, but innovative drugs like PCSK9 inhibitors are gaining traction [12][22] Competitive Landscape - The market is experiencing significant changes, with foreign companies like Pfizer and Sanofi leading the high-end market, while local firms like Yuyuan Health and Jingxin Pharmaceutical focus on mid to low-end markets [14][16] - Competition is shifting from price to efficacy, safety, and brand service, with an expected increase in market concentration through mergers and international collaborations [14][22] Company Highlights - Jingxin Pharmaceutical focuses on the development and sales of statins and is expanding into combination therapies and new drug targets [16] - Yuyuan Health has developed a PCSK9-targeting siRNA drug, YKYY015, which is in clinical trials and has received IND approval in the U.S. [18] - The revenue of Yuyuan Health is projected to decline by 9.9% in 2024, with cardiovascular drug sales down by 20.73% [18] Future Trends - The market for cholesterol-lowering drugs is expected to continue expanding due to an increasing patient population and unmet treatment needs, with projections indicating a compound annual growth rate above a certain percentage [20][21] - Innovation in drug development is on the rise, with companies investing in new targets like Lp(a) and PCSK9 inhibitors, enhancing treatment options for patients [21][22]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5][16]. Core Views - The company achieved a revenue of 2.631 billion yuan in 2024, representing a year-on-year growth of 4.10%, and a net profit attributable to shareholders of 56 million yuan, reflecting a significant increase of 104.45% [1][4]. - The growth is primarily driven by breakthroughs in the formulation business and a rapid increase in non-sartan raw materials [1][2]. - The company is expected to diversify its business further, with stable cash flow from sartan products and accelerated growth from non-sartan, CDMO, and formulation segments [4]. Summary by Sections Financial Performance - In Q1 2025, the company reported a revenue of 759 million yuan, a year-on-year increase of 10.13%, and a net profit of 86 million yuan, up 112.71% [1]. - The sales volume of sartan raw materials reached 1,744 tons in 2024, a growth of approximately 13%, while non-sartan raw materials saw a remarkable increase of 169%, reaching 124 tons [2]. - The formulation business generated sales of 255 million yuan in 2024, marking a 143% increase compared to the previous year [3]. Business Segments - The company has a rich reserve of non-sartan raw materials, including key products like sitagliptin and montelukast, with 20 new projects initiated and 12 products completing process validation in 2024 [2]. - The formulation segment has expanded its presence in national procurement, with two products winning bids and 18 products selected for provincial renewals [3]. Future Outlook - Revenue projections for 2025-2027 are set at 2.965 billion yuan, 3.413 billion yuan, and 3.704 billion yuan, respectively, with net profits expected to reach 284 million yuan, 418 million yuan, and 484 million yuan [4][10]. - The company is enhancing its international registration efforts and advancing its global expansion strategy, anticipating continued demand growth as patents for non-sartan products expire [2][4].

法律意见书 浙江天册律师事务所 关于 浙江天宇药业股份有限公司 2024 年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江天宇药业股份有限公司 2024 年度股东大会的 法律意见书 编号：TCYJS2025H0625 号 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和该等议案中所表述的事实或数据 的真实性和准确性发表意见。 本法律意见书仅供天宇股份 2024 年度股东大会之目的使用。本所律师同意将 本法律意见书随天宇股份本次股东大会其他信息披露资料一并公告，并依法对本 所在其中发表的法律意见承担法律责任。 本所律师根据相关法律、法规的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对天宇股份本次股东大会所涉及的有关事项和相关文件 进行了必要的核查和验证，同时听取了公司就有关事实的陈述和说明。现出具法 律意见如下： 一、本次股东大会召集、召开的程序 （一）经本所律师核查，公司本 ...